Avinger (Avinger) Risk Assessment

View and export this data going back to 2015. Start your Free Trial

What is Avinger Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Avinger is: High Risk: High uncertainty.

Competitive Comparison of Avinger's Risk Assessment

For the Medical Instruments & Supplies subindustry, Avinger's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avinger's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avinger's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Avinger's Risk Assessment falls into.

Avinger (NAS:AVGR) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Avinger Risk Assessment Related Terms

Thank you for viewing the detailed overview of Avinger's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Avinger (Avinger) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Avinger Inc (NAS:AVGR) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Chesapeake Drive, Redwood City, CA, USA, 94063

Website

https://avinger.com

Avinger Inc is a United States-based medical device company. It is engaged in designing, manufacturing and selling image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). The products offered by the firm include Lightbox imaging console, the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO) and Pantheris, image-guided atherectomy device which is designed to allow physicians to precisely remove arterial plaque in PAD patients. It manufactures and sells products in the United States and internationally of which it generates the majority of the revenue from the sales made in the United States.

Executives

Crg Partners Iii (cayman) Unlev Aiv I L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Lev Aiv I L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund B (cayman) L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Cr Group L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund (a) L.p.	10 percent owner	C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Nabeel Paul Subainati	officer: Vice President, Finance	400 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
James Cullen	director	5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Mark Weinswig	officer: Chief Financial Officer	EMCORE CORP, 10420 RESEARCH ROAD, SE, ALBUQUERQUE NM 87123
Himanshu Patel	officer: Chief Technology Officer	C/O AVINGER, INC., 400 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Jeffrey M Soinski	director, officer: President and CEO	585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Tamara Elias	director	400 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Simpson John B Ph D Md	director, 10 percent owner	C/O FOXHOLLOW TECHNOLOGIES, INC., 740 BAY ROAD, REDWOOD CITY CA 94063
Matthew Ferguson	officer: CBO, CFO & Treasurer	C/O FOXHOLLOW TECHNOLOGIES, INC., 740 BAY ROAD, REDWOOD CITY CA 94063
John D. Simpson	officer: Sr. VP, Sales & Marketing	C/O AVINGER, INC., 400 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063